Atara Biotherapeutics Inc (ATRA)
$0.7147
Insights on Atara Biotherapeutics Inc
Increasing Revenue
Revenue is up for the last 3 quarters, 957.0K → 4.25M (in $), with an average increase of 52.5% per quarter
Increasing Net Profit
Netprofit is up for the last 4 quarters, -74.77M → -60.45M (in $), with an average increase of 7.5% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 127.5%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 342.3%
Performance
- $0.69$0.74$0.71
2.8%
Downside
Day's Volatility :6.31%
Upside
3.61%
- $0.20$3.02$0.71
72.03%
Downside
52 Weeks Volatility :93.42%
Upside
76.49%
Returns
| Period | Atara Biotherapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 19.15% | 2.0% | 0.0% |
6 Months | -45.56% | 11.7% | 0.0% |
1 Year | -74.87% | 5.8% | 1.3% |
3 Years | -95.04% | 14.2% | -22.1% |
Highlights
Market Capitalization | 83.2M |
Book Value | - $0.93 |
Earnings Per Share (EPS) | -2.61 |
PEG Ratio | 0.0 |
Wall Street Target Price | 4.2 |
Profit Margin | 0.0% |
Operating Margin TTM | -1922.44% |
Return On Assets TTM | -62.11% |
Return On Equity TTM | -2014.86% |
Revenue TTM | 8.6M |
Revenue Per Share TTM | 0.08 |
Quarterly Revenue Growth YOY | 1345.7% |
Gross Profit TTM | 63.6M |
EBITDA | -264.4M |
Diluted Eps TTM | -2.61 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.72 |
EPS Estimate Next Year | -0.46 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.47 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 487.66%
Technicals Summary
Sell
Neutral
Buy
Atara Biotherapeutics Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Atara Biotherapeutics Inc | 7.27% | -45.56% | -74.87% | -95.04% | -97.85% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Atara Biotherapeutics Inc | NA | NA | 0.0 | -0.72 | -20.15 | -0.62 | NA | -0.93 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Atara Biotherapeutics Inc | Buy | $83.2M | -97.85% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
Institutional Holdings
EcoR1 Capital, LLC
9.88%BlackRock Inc
6.95%Vanguard Group Inc
6.56%Redmile Group, LLC
6.16%D. E. Shaw & Co LP
3.84%UBS Group AG
3.62%
Corporate Announcements
Atara Biotherapeutics Inc Earnings
Atara Biotherapeutics Inc’s price-to-earnings ratio stands at None
Read More
Company Information
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Organization | Atara Biotherapeutics Inc |
Employees | 225 |
CEO | Dr. Pascal Touchon D.V.M. |
Industry | Health Technology |
